BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-5 out of 5 found
  Current Search:  emend: 5     

HTML
100%
Idera Pharmaceuticals Announces the Appointment of Malcolm MacCoss, Ph.D., to Its Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc.

(Nasdaq Dr.

MacCoss extensive accomplishments include critical contributions to bringing many important drugs to market, said James B.

Wyngaarden, M.D., Chairman of Idera.

We welcome Dr.

Business Wire via Yahoo!:  Jan 26 2010 2:09PM
Matching: emend
Find similar documents
HTML
100%
Elan Drug gets Japanese nod for product using NanoCrystal technology
Elan Drug Technologies, a business unit of Elan Corporation, plc announced the approval by the Japanese Ministry of Health, Labour and Welfare of Emend (aprepitant) for the treatment of cancer chemotherapy-induced nausea and vomiting.

Emend, which...

PharmaBiz:  Dec 16 2009 9:45AM
Matching: emend
Find similar documents
HTML
100%
Elan Drug Technologies Announces First Japanese Approval of Product Using Its NanoCrystal Technology
- Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) announces the approval by the Japanese Ministry of Health, Labour and Welfare of EMEND (aprepitant) for the treatment of cancer chemotherapy-induced nausea and vomiting.

...

Pharma Live:  Dec 14 2009 4:35PM
Matching: emend
Find similar documents
HTML
100%
Elan Drug Technologies Announces First Japanese Approval of Product Using Its NanoCrystal Technology
2009-12-14 02:00 ET - ReleaseCompany Website: DUBLIN -- (Business Wire) Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ) announces the approval by the Japanese Ministry of Health, Labour and Welfare of EMEND (aprepitant) for the...
Stockwatch:  Dec 14 2009 7:03AM
Matching: emend
Find similar documents
HTML
100%
Elan Drug Technologies Announces First Japanese Approval of Product Using Its NanoCrystal Technology
DUBLIN--(BUSINESS WIRE)--Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN - News) announces the approval by the Japanese Ministry of Health, Labour and Welfare of EMEND (aprepitant) for the treatment of cancer chemotherapy...
Business Wire via Yahoo!:  Dec 14 2009 7:02AM
Matching: emend
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.